---
title: "Rinzimetostat (ORIC-944) in Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide: Incidence"
description: "Formulary evidence on Rinzimetostat (ORIC-944) in Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide: Incidence. Topics: Estimated U.S. new cases in 2026, all prostate cancer stages; U.S. incidence rate, all prostate cancer stages; Distant-stage disease at diagnosis, all prostate cancer; U.S. incidence trend of regional-stage and distant-stage prostate cancer; 3 further topics. 7 evidence topics quoted from 5 sources."
canonical: "https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/product-information-and-disease-description/incidence"
published: "2026-11-15T21:45:22-05:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Rinzimetostat (ORIC-944) in Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide: Incidence

<a id="heading-2.2.1.2.1"></a>

## 2.2.1.2.1 Incidence of Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide

<a id="topic-2.2.1.2.1-1"></a>

### Estimated U.S. new cases in 2026, all prostate cancer stages

| Measure | Quoted value |
| --- | --- |
| Estimated new cases of prostate cancer, United States, 2026 | “333,830” |

Source: [Siegel et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12798275/)

> “In 2026, it is estimated that there will be 333,830 new cases of prostate cancer and an estimated 36,320 people will die of this disease.”

Source: [National Cancer Institute SEER Cancer Stat Facts](https://seer.cancer.gov/statfacts/html/prost.html)

<a id="topic-2.2.1.2.1-2"></a>

### U.S. incidence rate, all prostate cancer stages

> “The rate of new cases of prostate cancer was 123.2 per 100,000 men per year. The death rate was 18.9 per 100,000 men per year. These rates are age-adjusted and based on 2019–2023 cases and 2020–2024 deaths.”

Source: [National Cancer Institute SEER Cancer Stat Facts](https://seer.cancer.gov/statfacts/html/prost.html)

<a id="topic-2.2.1.2.1-3"></a>

### Distant-stage disease at diagnosis, all prostate cancer

| SEER measure | Quoted value |
| --- | --- |
| Percentage of cases diagnosed at distant stage | “9%” |

Source: [National Cancer Institute SEER Cancer Stat Facts](https://seer.cancer.gov/statfacts/html/prost.html)

<a id="topic-2.2.1.2.1-4"></a>

### U.S. incidence trend of regional-stage and distant-stage prostate cancer

> “From 2014 through 2022, the prostate cancer incidence rate rose by 2.9% per year (Table 5), with a longer and steeper slope for regional‐stage (4.6% per year since 2013) and distant‐stage (5.6% per year since 2011) disease.”

Source: [Siegel et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12798275/)

<a id="topic-2.2.1.2.1-5"></a>

### Modeled U.S. annual incidence of metastatic castration-resistant prostate cancer, 2009 and 2020

> “The model estimated the prevalence of prostate cancer as 2,219,280 in the US in 2009 and 3,072,480 in 2020, and incidence of mCRPC as 36,100 and 42,970, respectively.”
> “The majority (86%) of incidence flow into mCRPC states was from the nmCRPC clinical state.”

Source: [Scher et al. (2015)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4603789/)

<a id="topic-2.2.1.2.1-6"></a>

### Newly diagnosed metastatic castration-resistant prostate cancer in Medicare fee-for-service, 2014 to 2019

> “Men newly diagnosed with mCRPC were identified in Medicare fee-for-service claims during 1/1/2014–6/30/2019.”
> “The final study population consisted of 14,780 men”

Source: [Freedland et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11096091/)

<a id="topic-2.2.1.2.1-7"></a>

### Company estimate: U.S. annual incidence of metastatic castration-resistant prostate cancer after abiraterone

> “In the US, the annual incidence of mCRPC patients previously treated with abiraterone is approximately 17,000, with an estimated addressable market of greater than $3.5 billion and total global addressable market of $7 billion.”

Source: [ORIC Pharmaceuticals RP3D selection release (2026)](https://oricpharma.com/news/oric-pharmaceuticals-reports-selection-of-rinzimetostat-rp3d-in-combination-with-darolutamide-for-himalayas-1-phase-3-global-study-with-dose-optimization-data-supporting-its-potential-best-in-di/)

## Related pages
- [Rinzimetostat (ORIC-944): Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide) · [Markdown](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide.md)
- [Rinzimetostat (ORIC-944) in Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide: Terms and abbreviations](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/terms-and-abbreviations.md)
- [Rinzimetostat (ORIC-944): Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/executive-summary) · [Markdown](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/executive-summary.md)
- [Rinzimetostat (ORIC-944) in Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide: Product information and disease description](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/product-information-and-disease-description.md)
- [Rinzimetostat (ORIC-944) in Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide: Clinical evidence](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/clinical-evidence.md)
- [Rinzimetostat (ORIC-944) in Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide: Economic information and modeling report](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/economics) · [Markdown](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/economics.md)
- [Rinzimetostat (ORIC-944) in Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide: References](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/references) · [Markdown](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/references.md)
